Compare HAYW & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAYW | NUVB |
|---|---|---|
| Founded | 1925 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.9B |
| IPO Year | 2021 | N/A |
| Metric | HAYW | NUVB |
|---|---|---|
| Price | $17.00 | $5.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $18.00 | $10.89 |
| AVG Volume (30 Days) | 1.7M | ★ 6.5M |
| Earning Date | 02-25-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.13 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $1,099,855,000.00 | $26,748,000.00 |
| Revenue This Year | $7.17 | $636.92 |
| Revenue Next Year | $5.24 | $191.15 |
| P/E Ratio | $26.82 | ★ N/A |
| Revenue Growth | 9.66 | ★ 1137.19 |
| 52 Week Low | $11.10 | $1.54 |
| 52 Week High | $17.73 | $9.75 |
| Indicator | HAYW | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 41.38 |
| Support Level | $15.36 | $5.31 |
| Resistance Level | $16.36 | $6.22 |
| Average True Range (ATR) | 0.44 | 0.37 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 97.05 | 62.83 |
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.